Real-world data catalogs established by the Heads of Medicines Agencies and the European Medicines Agency (HMA–EMA RWD catalogues) represent a centralized digital approach for broad access to reliable data to ensure patient safety. In this study, RWD catalog analysis was conducted in order to identify best practices and challenges, focusing on finalized non-interventional studies (NISs) with a scope specified as ‘safety’. The results (n = 240) show a predominance of studies required by a pharmaceutical regulator (56.6%) as well as the importance of NIS in pharmacovigilance via inclusion in risk management plans (RMPs) (52%) and broad use of NIS in risk minimization measure (RMM) evaluation. However, the lack of a unified regulatory framework, insufficient published data, and the recognized need for digital tool implementation create the necessity for improvement within the European Union (EU) pharmaceutical legislation.
17 September 2025 in European Journal of Hospital Pharmacy
Moxifloxacin is a fourth-generation fluoroquinolone with a broad spectrum of antibacterial activity. It is commonly used for both local and systemic applications. Data on the safety profile of fluoroquinolones indicate the potential for serious adverse reactions including neurological and psychiatric disturbances. The current case describes the off-label use of moxifloxacin eye drops for nasal administration in a toddler which led to insomnia and symptoms of severe psychosis. Notably, these adverse events resolved completely shortly after discontinuation of treatment. This case highlights a rare and potentially debilitating adverse reaction and underscores the critical importance of clinical judgement when prescribing off-label medicines in the paediatric population.